Search Results
Your search for early matches 10332 pages
Showing 1101 - 1150W. Kimryn Rathmell, MD, PhD, Begins Work as 17th Director of the NCI
On December 18, W. Kimryn Rathmell, MD, PhD, began her work as the 17th Director of the National Cancer Institute (NCI). Dr. Rathmell was selected by President Biden to succeed Monica M. Bertagnolli, MD, FACS, FASCO, who left NCI to become the Director of the National Institutes of Health (NIH) on...
Daniel Kates-Harbeck, MD Candidate, and Nadia Harbeck, MD, PhD, on Personalizing Breast Cancer Management With AI: Novel Approach to Predicting Outcomes
Nadia Harbeck, MD, PhD, of LMU University Hospital and Ludwig Maximilian University of Munich, and Daniel Kates-Harbeck, of the West German Study Group and an MD Candidate at Ludwig Maximilian University of Munich, discuss a learning-based neural network developed by Mr. Kates-Harbeck to predict...
Oleg Gluz, MD, on Response to Endocrine Therapy: Findings From the ADAPTcycle Trial
Oleg Gluz, MD, of the West German Study Group and Breast Center Niederrhein, discusses the impact of age and ovarian function suppression in response to preoperative endocrine treatment for both pre- and postmenopausal patients with early-stage breast cancer. He describes ways in which the outcome...
Use of Elranatamab for Black Patients With Multiple Myeloma
Elranatamab may be safe and effective in Black patients with relapsed or refractory multiple myeloma, according to new findings presented by Varshavsky-Yanovsky et al at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 3333). Background Elranatamab—an...
Revumenib in High-Risk KMT2A-Rearranged Acute Leukemia
Patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2A gene, a genetic marker known as KMT2A, who were treated with revumenib, a small-molecule inhibitor of menin-KMT2A interactions, saw an overall response rate of 63%, according to results from...
Menin Inhibitors in Patients With Advanced AML and Gene Mutations
Two new studies have demonstrated positive results from novel therapies targeting menin for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with specific gene mutations, according to findings presented by Jabbour et al (Abstract 57) and Issa et al (Abstract 58) at ...
Novel CAR T-Cell Therapy May Show Early Efficacy in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Early results from a new study have demonstrated that the novel chimeric antigen receptor (CAR) T-cell therapy AT101 resulted in favorable complete response rates at higher dose levels in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, according to new findings simultaneously...
Aditya Bardia, MD, MPH, on Early-Stage, High-Risk Breast Cancer: New Data on Pembrolizumab Plus Chemotherapy
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses phase III findings from the KEYNOTE-756 study, which showed that adding pembrolizumab to chemotherapy increases the pathologic complete response rate and lowers the residual cancer burden in patients with...
Daniel G. Stover, MD, on Early-Stage Breast Cancer: A Biomarker Analysis From the PALLAS Trial
Daniel G. Stover, MD, of The Ohio State University Comprehensive Cancer Center, discusses a biomarker analysis from the PALLAS adjuvant trial, which compared 2 years of the CDK4/6 inhibitor palbociclib with endocrine therapy vs endocrine therapy alone, as adjuvant treatment for patients with stage...
Autologous Stem Cell Transplant vs CAR T-Cell Therapy in Patients With Relapsed LBCL in Complete Remission
For patients with large B-cell lymphoma (LBCL) who have an early relapse or whose cancer doesn’t respond to first-line treatment, randomized trials have shown that chimeric antigen receptor (CAR) T-cell therapy is superior to the historical standard of care, which included additional chemotherapy...
Psychiatric and Substance Use Disorders May Be Linked to Poorer Outcomes in AML Following Venetoclax Combination Therapies
Researchers have found that patients with psychiatric or substance use disorders may have an increased risk of experiencing poorer outcomes such as early mortality following treatment for acute myeloid leukemia (AML) with venetoclax combination therapies compared with those without a recent history ...
Nicholas C. Turner, MD, PhD, on High-Risk Early-Stage Breast Cancer: Profiling Primary Tumors
Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Foundation Trust, and the Institute of Cancer Research, London, discusses the monarchE trial, which evaluated molecular profiling of archived primary tumor tissue from patients with hormone receptor–positive, HER2-negative,...
Gabriel N. Hortobagyi, MD, on Early Breast Cancer: Final Invasive Disease–Free Analysis From the NATALEE Trial
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the NATALEE trial, which continued to demonstrate improved invasive disease–free survival with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with...
New Guideline Offers Much-Needed Support in the Treatment of Neuroendocrine Tumors
An ASCO guideline has been developed to inform the use of systemic treatments for metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).1 The guideline helps fill a knowledge gap among community oncologists in particular, who typically do not see many of these rare ...
BEATcc Trial: Atezolizumab-Based Regimen Improves Outcomes in First-Line Setting for Advanced Cervical Cancer
In patients with recurrent or metastatic cervical cancer, the addition of the PD-L1–inhibiting monoclonal antibody atezolizumab to first-line chemotherapy plus the angiogenesis inhibitor bevacizumab significantly improved all efficacy outcomes and yielded a median overall survival that exceeded 2.5 ...
Expert Point of View: Elizabeth Smyth, MD
ASCO discussant Elizabeth Smyth, MD, a consultant medical oncologist at Oxford University Hospitals National Health Service Foundation Trust in the United Kingdom, commented on the EDGE-Gastric trial. This regimen, which evaluated dual checkpoint blockade with next-generation agents, aims to...
Early Data Show Novel Immunotherapy Regimen May Improve Outcomes in Advanced Gastric Cancer
Initial findings from the global phase II EDGE-Gastric trial indicate the potential for two novel immune checkpoint inhibitors to improve outcomes in advanced gastroesophageal adenocarcinoma. The findings were reported at the November 2023 ASCO Plenary Session by Yelena Y. Janjigian, MD, Chief of...
Combining Ribociclib With Hormone Therapy Improves Patient Outcomes in Early-Stage Breast Cancer: NATALEE
Targeted treatment with ribociclib plus hormone therapy provided significant invasive disease–free survival benefits in patients with early-stage hormone receptor–positive, HER2-negative breast cancer at risk of disease recurrence. Results from the phase III NATALEE trial, led by researchers at The ...
Supportive Parents and Early Love of Science Lead to a Career in Hematology Oncology for Nina Shah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Nina Shah, MD, Global Head of Multiple Myeloma Clinical Development and Strategy, Hematology, Oncology Research and Development at AstraZeneca. She is a hematologist who specializes in...
American Cancer Society Releases Updated Lung Cancer Screening Guideline
Lung cancer incidence overall has been declining in the United States since 1992—and since 2006–2007 for both men and women by 2.7% annually and 1.1%, respectively—and overall mortality rates have declined in both men and women because of smoking cessation efforts and advances in therapy and early...
Expert Point of View: Upal Basu Roy, PhD, MPH
Upal Basu Roy, PhD, MPH, Executive Director of Research at the LUNGevity Foundation, in Chicago, shared his thoughts with The ASCO Post on the INCREASE trial’s findings and their potential impact on clinical practice. As Dr. Roy explained, neoadjuvant chemoimmunotherapy remains the current standard ...
Sustained MRD Negativity Achieved With Isa-KRd in Newly Diagnosed Multiple Myeloma
For the treatment of newly diagnosed multiple myeloma with high-risk features, a quadruplet regimen of the anti-CD38 antibody isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) induced high rates of measurable residual disease (MRD) negativity, both in transplant-eligible and...
Some Breast Cancer Survivors May Safely De-escalate Mammography 3 Years After Surgery
Women aged 50 or older who had less-frequent mammography 3 years after curative surgery for early-stage breast cancer had similar outcomes as women who had annual mammography, according to results from the Mammo-50 trial presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS03-02)....
Recipients of 2023 Susan G. Komen Breast Cancer Awards Honored
Susan G. Komen presented its 2023 Breast Cancer Awards to four physician-scientists and one research advocate for their contributions to advancing breast cancer discoveries and improving patient outcomes. The five recipients were recognized at the Susan G. Komen Breast Cancer Awards event in San...
Using Estrogen Levels to Predict Who May Benefit From Preventive Treatment With Anastrozole
Investigators have found that estrogen levels measured through blood tests may be predictive of which individuals at high risk of breast cancer will benefit from aromatase inhibitors, according to a recent study presented by Cuzick et al at the 2023 San Antonio Breast Cancer Symposium (Abstract...
Understanding the Treatment Options for PD-1–Refractory Melanoma
For the treatment of advanced melanoma that is refractory to anti–PD-1 antibodies, there is no standard approach. The various options, with a look to the future, were discussed by Melinda L. Yushak, MD, MPH, Assistant Professor of Hematology and Oncology at Emory University School of Medicine, at...
Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy
Almost all postmenopausal patients aged 50 to 69 with stage I hormone receptor–positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease-free 5 years after surgery, according to results from the IDEA clinical trial presented at the 2023 San...
Novel Targeted Therapies May Benefit Patients With Metastatic Hormone Receptor–Positive/HER2-Negative Breast Cancer
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor–positive/HER2-negative breast cancer. The data were shared in oral...
Risk Model May Accurately Predict Aromatase Inhibitor Nonadherence
A novel risk model may be effective at using baseline sociodemographic and financial measures to predict the risk of long-term aromatase inhibitor nonadherence among patients with breast cancer, according to new findings presented by Hershman et al at the 2023 San Antonio Breast Cancer Symposium...
CAR T-Cell Therapy May Be Effective—but Unaffordable—as Second-Line Therapy for Patients With DLBCL
Investigators have found that chimeric antigen receptor (CAR) T-cell therapy may be an effective but unaffordable second-line treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Kelkar et al in the Annals of Internal Medicine....
Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
A combination of two HER2-targeted drugs—tucatinib and ado-trastuzumab emtansine (T-DM1), extended progression-free survival among patients with unresectable, locally advanced, or metastatic HER2-positive breast cancer compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial...
Regular Screening Mammograms May Significantly Reduce Breast Cancer Mortality, Swedish Study Shows
Patients who regularly attend screening mammograms may have a reduced risk of breast cancer mortality, according to recent findings presented by Smith et al at the Radiological Society of North America (RSNA) 2023 Scientific Assembly and Annual Meeting (Abstract R1-SSBR10-4). Background Early...
Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC
In the phase II SPRINT trial reported in the Journal of Clinical Oncology, Ohri et al found that a chemotherapy-sparing regimen of pembrolizumab with risk-adapted radiotherapy was associated with good outcomes in patients with stage III or unresectable stage II non–small cell lung cancer (NSCLC)...
Highlights From the ESMO Congress 2023
The European Society for Medical Oncology (ESMO) Congress 2023 held in Madrid reported out several eagerly awaited and potentially practice-changing trials, bringing forward promising new combination strategies in the targeted and immunotherapy space, and put to the test selective agents against...
CodeBreaK 300: Sotorasib Plus Panitumumab of Benefit in KRAS-Mutated Metastatic Colorectal Cancer
The combination of sotorasib and panitumumab significantly improved progression-free survival compared with standard treatment in patients with chemotherapy-refractory metastatic colorectal cancer with KRAS G12C mutations, the phase III CodeBreaK 300 trial has shown. The KRAS G12C inhibitor...
Two Studies Show Improved Survival With Novel Front-Line Combinations in Advanced Urothelial Carcinoma
Two phase III trials presented at a Presidential Symposium during the European Society for Medical Oncology (ESMO) Congress 2023 showed an overall survival benefit for patients with advanced urothelial cancer. The results from both studies were hailed as practice-changing. The EV-302/KEYNOTE-A39...
First-Line Selpercatinib: New Standard of Care for RET-Positive Medullary Thyroid Cancer?
First-line treatment with selpercatinib achieved a statistically significant improvement in progression-free survival and overall response rate vs treatment with cabozantinib or vandetanib in patients with multikinase inhibitor–naive, RET-mutant advanced or metastatic medullary thyroid cancer.1 At...
Novel AI Model May Predict Nonsmokers at High Risk for Lung Cancer
An artificial intelligence (AI) model may be capable of using routine chest x-ray images to identify nonsmokers who may be at high risk for lung cancer, according to new findings presented by Walia et al at the Radiological Society of North American (RSNA) 2023 Scientific Assembly and Annual...
Expert Point of View: Marina C. Garassino, MD
Formal discussant of the ALINA trial Marina C. Garassino, MD, of the University of Chicago, agreed these results are “impressive and practice changing.” However, she said, at this point, more consideration is needed before jettisoning chemotherapy. “I don’t think we should stop giving adjuvant...
ALINA Trial: Anticancer Activity of Alectinib Reported in Earlier-Stage, ALK-Positive NSCLC
Treatment with the anaplastic lymphoma kinase (ALK) inhibitor alectinib significantly reduced the risk of recurrence or death by 76% (P < .0001) in patients with completely resected stage IB to IIIA ALK-positive non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy. This...
Expert Point of View: Zofia Piotrowska, MD
Zofia Piotrowska, MD, of the Massachusetts General Hospital/Harvard Medical School, Boston, noted that MARIPOSA and MARIPOSA-2 are “two well-designed, randomized phase III trials, each meeting its primary endpoints and representing important advances for patients with EGFR-mutant lung cancer.”...
Amivantamab-Based Regimens Show Anticancer Activity in EGFR-Mutated Advanced NSCLC
Widely anticipated findings from the MARIPOSA1 and MARIPOSA-22 trials were presented at the European Society for Medical Oncology (ESMO) Congress 2023, showing potentially improved outcomes with regimens incorporating the bispecific antibody amivantamab-vmjw for patients with advanced non–small...
PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs Progression-Free Survival in NSCLC Subset
In the phase III PAPILLON trial, the addition of the bispecific antibody amivantamab-vmjw to chemotherapy resulted in a near doubling in median progression-free survival vs chemotherapy alone in patients with untreated non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR)...
Urban Environmental Exposures and Incidence of Breast Cancer
Investigators have uncovered that North Carolina’s urban counties may have higher overall incidences of breast cancer than its rural counties, especially at early stages at diagnosis, according to a recent study published by Gearhart-Serna et al in Scientific Reports. These findings may serve as a...
Expert Point of View: Upal Basu Roy, PhD, MPH
Upal Basu Roy, PhD, MPH, Executive Director of Research at the LUNGevity Foundation, in Chicago, shared his thoughts with The ASCO Post on the INCREASE trial’s findings and their potential impact on clinical practice. As Dr. Roy explained, neoadjuvant chemoimmunotherapy remains the current standard ...
Expert Point of View: Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD, cautioned that although FLAURA2 is a positive result, most patients will still develop drug resistance. “The result is really good and clearly positive, but if you look at the survival curves, there is still early overlap in a way that makes it unlikely this combination will ...
Expert Point of View: Gerard A. Silvestri, MD, MS
Gerard A. Silvestri, MD, MS, the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina, Charleston, praised the investigators of the Taiwan National Lung Cancer Screening Program for their accomplishment. “It’s incredible that they screened almost 50,000...
Taiwan National Lung Cancer Early Detection Screening Program Targets Smokers and Nonsmokers With Family History
Findings from the Taiwan National Lung Cancer Early Detection Program have shown that lung cancer screening by low-dose computed tomography (CT) can detect tumors at an early-enough phase to allow for effective intervention. In a recent analysis, 85% of tumors detected by screening were stage 0 or...
Extended Pleurectomy Decortication Plus Chemotherapy for Mesothelioma Linked to Increased Risk of Death in MARS-2 Trial
The results of a recent study from the United Kingdom could spell the end of a long-standing treatment strategy for mesothelioma, according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer.1 When combined with...
Highlights From the 2023 World Conference on Lung Cancer
The management of lung cancer and other thoracic malignancies has evolved significantly over the past decade. Thanks to many scientific advancements in the field, new therapeutic options, and improvements in screening and early detection, more patients are being cured, and many others are living...
